Neurological recovery from B12 deficiency typically takes months, though some patients report reduced symptoms within weeks of starting treatment
In agreement with these findings, reduced numbers of progenitor cells were observed in the SVZ of AD patients using Mushashi as a marker, although the number of Nestin-positive stem cells was actually increased in that study (Ziabreva et al., 2006)
Like all medications, some of these side effects are more common than others
The related Athira compound fosgonimeton failed its Phase 2 Alzheimer's trial (LIFT-AD) in 2023 for efficacy, and Athira discontinued development
Preclinical studies demonstrated that AOD-9604 was generally safe after chronic oral application in rats and cynomolgus monkeys, with no genotoxic concerns identified
Breast ducts increase due to estrogen, while milk glands enlarge due to progesterone